ED
CVS icon

Exane Derivatives’s CVS Health CVS Stock Holding History

Exane Derivatives’s Portfolio CVS Stock Details CVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$426K Buy
4,597
+3,885
+546% +$379K 0.24% 103
2022
Q1 		$72.1K Sell
712
-363
-34% -$38.1K 0.02% 516
2021
Q4 		$111K Buy
1,075
+744
+225% +$68.8K 0.03% 430
2021
Q3 		$28.1K Hold
331
– – 0.01% 668
2021
Q2 		$27K Buy
+331
New +$27.1K 0.01% 687
2021
Q1 		– Sell
-1,511
Closed -$103K – 938
2020
Q4 		$103K Buy
1,511
+12
+0.8% +$781 0.03% 394
2020
Q3 		$87.5K Sell
1,499
-6,759
-82% -$421K 0.03% 314
2020
Q2 		$537K Buy
8,258
+4,012
+94% +$253K 0.14% 125
2020
Q1 		$252K Sell
4,246
-2,543
-37% -$170K 0.07% 173
2019
Q4 		$511K Sell
6,789
-10,426
-61% -$732K 0.09% 165
2019
Q3 		$1.09M Buy
17,215
+3,868
+29% +$229K 0.19% 105
2019
Q2 		$727K Buy
13,347
+10,303
+338% +$555K 0.13% 131
2019
Q1 		$164K Sell
3,044
-18,003
-86% -$1.11M 0.03% 241
2018
Q4 		$1.38M Sell
21,047
-1,924
-8% -$144K 0.25% 95
2018
Q3 		$1.81M Sell
22,971
-33,371
-59% -$2.39M 0.34% 79
2018
Q2 		$3.62M Buy
56,342
+22,154
+65% +$1.46M 0.61% 28
2018
Q1 		$2.14M Buy
34,188
+22,543
+194% +$1.62M 0.43% 58
2017
Q4 		$844K Buy
11,645
+11,079
+1,957% +$805K 0.15% 111
2017
Q3 		$46K Sell
566
-1,961
-78% -$155K 0.01% 313
2017
Q2 		$203K Buy
2,527
+1,045
+71% +$82.5K 0.04% 201
2017
Q1 		$116K Sell
1,482
-141
-9% -$11.3K 0.03% 219
2016
Q4 		$128K Sell
1,623
-87,370
-98% -$7.07M 0.03% 231
2016
Q3 		$7.92M Buy
88,993
+86,997
+4,359% +$8.21M 1.19% 31
2016
Q2 		$191K Sell
1,996
-240
-11% -$23.9K 0.03% 205
2016
Q1 		$232K Sell
2,236
-637
-22% -$61.9K 0.03% 184
2015
Q4 		$281K Buy
2,873
+1,069
+59% +$105K 0.04% 145
2015
Q3 		$174K Sell
1,804
-224,828
-99% -$23.6M 0.02% 195
2015
Q2 		$23.8M Buy
226,632
+14,062
+7% +$1.44M 2.56% 6
2015
Q1 		$21.9M Buy
212,570
+71,612
+51% +$7.25M 2.42% 15
2014
Q4 		$13.6M Buy
+140,958
New +$12.4M 1.88% 8

Other funds holding CVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Exane Derivatives's CVS Position: Q2 2022 in Review

Exane Derivatives increased its CVS Health (CVS) stake by 546% in Q2 2022, buying an estimated $379K and bringing the position to 4,597 shares worth $426K. The position accounts for 0.24% of the portfolio, ranked #103.

Exane Derivatives first reported a position in CVS in Q4 2014 and has held it in 30 quarters since. The position peaked at $23.8M in Q2 2015. 2,308 funds tracked by Wall St. Rank hold CVS as of Q2 2022.

  • Exane Derivatives held 4,597 shares of CVS Health worth $426K as of Q2 2022.
  • Exane Derivatives bought 3,885 CVS Health shares in Q2 2022, an estimated $379K.
  • CVS Health made up 0.24% of Exane Derivatives's portfolio in Q2 2022, its #103 holding.
  • Exane Derivatives first reported a position in CVS Health in Q4 2014 and has held it in 30 quarters since.
  • Exane Derivatives's CVS Health position peaked at $23.8M in Q2 2015.
  • 2,308 funds tracked by Wall St. Rank held CVS Health as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.